.png?width=700&name=New-ATE-Logo2019%20(1).png)
Accelerating ADC Drug Development with
Technology Innovation and an Integrated Platform
Presenter:
Bingquan (Stuart) Wang, PhDSenior Director, US-EU CMC Management,
WuXi XDC
Bingquan (Stuart) Wang, PhD is a senior director in US-EU CMC management at WuXi XDC. He joined WuXi Biologics (the parent company of WuXi XDC) in 2019, and has led many early and late-stage biologics and ADC projects. Prior to joining WuXi Bio, he had gained extensive CMC experiences from multiple companies including Moderna, Shire, Biogen, and Sanofi Genzyme. He received his doctoral degree in pharmaceutical sciences from the lab of Michael Pikal, PhD at the University of Connecticut, USA.
Wang, PhD has worked on different roles in formulation development, lyophilization, DP process development, scale-down model, tech transfer, scale up, and more. He has strong project stewardship and achieved many critical project milestones through working collaboratively with internal CMC teams and external partners. Wang, PhD has strong CMC experience in various modalities. He has led cross-functional efforts on late-stage development/process characterization, process validation, BLA dossier preparation, and life cycle management. He has authored multiple CMC sections of IND and BLA documents.
